|
gptkbp:instanceOf
|
gptkb:chemical_class
|
|
gptkbp:category
|
psychedelic phenethylamines
|
|
gptkbp:chemicalFormula
|
2,5-dimethoxyphenethylamine core
|
|
gptkbp:discoveredBy
|
gptkb:Alexander_Shulgin
|
|
gptkbp:durationOfEffects
|
4-8 hours (varies by compound)
|
|
gptkbp:effect
|
empathy
euphoria
hallucinations
altered perception
stimulation
|
|
gptkbp:firstDescribed
|
1970s
|
|
gptkbp:legalStatus
|
varies by country
|
|
gptkbp:mainStreet
|
2C drugs
2C's
|
|
gptkbp:mechanismOfAction
|
gptkb:serotonin_receptor_agonist
dopamine receptor activity (some members)
norepinephrine receptor activity (some members)
|
|
gptkbp:mentionedIn
|
gptkb:PiHKAL
|
|
gptkbp:molecularFormulaPattern
|
C10H15NO2 (varies by substitution)
|
|
gptkbp:notableMember
|
gptkb:2C-T-2
gptkb:2C-T-7
gptkb:2C-E
gptkb:2C-T-21
gptkb:2C-T-4
gptkb:2C-B
gptkb:2C-C
gptkb:2C-D
gptkb:2C-H
gptkb:2C-I
gptkb:2C-N
gptkb:2C-P
|
|
gptkbp:psychoactive
|
true
|
|
gptkbp:regulates
|
Class A in the United Kingdom (some members)
Schedule I in the United States (some members)
controlled in Australia (some members)
controlled in Canada (some members)
|
|
gptkbp:relatedTo
|
gptkb:DOx_family
gptkb:NBOMe_family
mescaline
|
|
gptkbp:riskFactor
|
overdose
legal prosecution
adverse psychological effects
|
|
gptkbp:routeOfAdministration
|
oral
insufflation
|
|
gptkbp:subclassOf
|
gptkb:phenethylamines
|
|
gptkbp:toxicity
|
varies by compound
|
|
gptkbp:type
|
gptkb:tablet
capsule
powder
|
|
gptkbp:usedFor
|
recreational purposes
psychedelic experiences
|
|
gptkbp:bfsParent
|
gptkb:NBOH
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
2C family
|